Five Years of Sacubitril/Valsartan—a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance.

MLA

Kim, Yee Soo, et al. “Five Years of Sacubitril/Valsartan—a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance.” Cardiovascular Drugs & Therapy, vol. 36, no. 5, Oct. 2022, pp. 915–24. EBSCOhost, https://doi.org/10.1007/s10557-021-07210-1.

APA

Kim, Y. S., Brar, S., D’Albo, N., Dey, A., Shah, S., Ganatra, S., & Dani, S. S. (2022). Five Years of Sacubitril/Valsartan—a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance. Cardiovascular Drugs & Therapy, 36(5), 915–924. https://doi.org/10.1007/s10557-021-07210-1

Chicago

Kim, Yee Soo, Simerjeet Brar, Natalie D’Albo, Amit Dey, Sachin Shah, Sarju Ganatra, and Sourbha S. Dani. 2022. “Five Years of Sacubitril/Valsartan—a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance.” Cardiovascular Drugs & Therapy 36 (5): 915–24. doi:10.1007/s10557-021-07210-1.